Enzelkitug - Genentech
Alternative Names: RG-6411; RO-7502175Latest Information Update: 29 Oct 2026
At a glance
- Originator Genentech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CCR8 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 29 Oct 2026 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Australia (IV)
- 29 Oct 2026 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Belgium (IV)
- 29 Oct 2026 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Canada (IV)